What if one of the most important questions in medicine isn't simply whether the evidence exists—but who had enough money and incentive to create that evidence in the first place?
We hear the phrase constantly:
“Follow the science.”
Good advice.
But science—especially large-scale clinical science—costs money.
Laboratories cost money.
Researchers cost money.
Manufacturing clinical-grade material costs money.
Clinical sites cost money.
Patient recruitment costs money.
Monitoring costs money.
Regulatory compliance costs money.
Long-term safety studies cost money.
So before a treatment can accumulate the mountain of evidence necessary to become accepted medicine, somebody usually has to finance that mountain.
And that raises a question that deserves far more attention:
WHO DECIDES WHICH QUESTIONS ARE WORTH PAYING TO ANSWER?
01LET'S START WITH A DOCUMENTED FACT
The pharmaceutical and health-product industry spends heavily on political influence.
A peer-reviewed JAMA Internal Medicine analysis examined political spending between 1999 and 2018.
It found that the pharmaceutical and health-product industry spent approximately $4.7 billion lobbying the federal government over those twenty years—an average of roughly $233 million per year.
The study also documented hundreds of millions of dollars in federal campaign contributions and substantial state-level contributions during the period analyzed.
Those are not numbers from a meme.
They come from published research analyzing publicly available political-spending data.
02DOES THAT PROVE FDA IS CONTROLLED BY BIG PHARMA?
No.
And this is exactly where credibility matters.
Lobbying expenditures demonstrate an attempt to influence government policy.
They do not establish that a particular regulatory decision was secretly purchased.
If someone wants to claim:
“FDA restricted BPC-157 because Pharmaceutical Company X paid Politician Y,”
they need evidence establishing that connection.
Lobbying data alone cannot do it.
But the opposite conclusion would be equally unreasonable:
“Billions of dollars in lobbying have no relevance to health policy.”
Organizations don't spend billions lobbying because public policy doesn't matter to them.
The rational position is:
Financial influence deserves scrutiny.
Specific allegations require specific evidence.
03“BIG PHARMA” ISN’T ONE PERSON IN A DARK ROOM
The phrase can be useful shorthand.
It can also make people intellectually lazy.
The pharmaceutical industry includes companies competing fiercely against one another.
One company's billion-dollar product can be another company's commercial threat.
Companies sue each other.
They race for patents.
They compete for market share.
They pursue different technologies.
They develop peptide medicines themselves.
So the idea that pharmaceutical companies oppose “peptides” as one unified category doesn't make much sense.
Peptide drugs can be extremely valuable pharmaceutical products.
The more sophisticated question is:
WHICH PEPTIDES ARE COMMERCIALLY ATTRACTIVE ENOUGH TO RECEIVE MASSIVE DEVELOPMENT INVESTMENT?
Now we're getting somewhere.
04IMAGINE TWO PROMISING MOLECULES
Call them Compound A and Compound B.
Early research suggests both may have therapeutic potential.
Compound A can receive strong patent protection.
It targets a large patient population.
If approved, the company may enjoy years of valuable market exclusivity.
Compound B is scientifically interesting too.
But protecting it commercially is difficult.
Competitors might be able to enter quickly.
Its market is smaller.
The cost of definitive trials could be enormous relative to the expected return.
A pharmaceutical executive has limited research capital.
Which compound receives the investment?
Probably Compound A.
Does that mean Compound B doesn't work?
No.
Does it mean Compound A works?
Not yet.
It means economics influenced which scientific question got funded first.
Financial incentives deserve investigation.
05THAT'S NOT A CONSPIRACY
It's capitalism.
Investors provide money because they expect a return.
Drug development is risky.
Many compounds fail.
A successful medicine has to help finance all the unsuccessful programs that consumed resources along the way.
Patents and exclusivity therefore serve a legitimate purpose:
They create incentives to invest in risky innovation.
Without those incentives, many life-changing medicines might never exist.
But every incentive system has blind spots.
And one potential blind spot is medically useful treatments that don't offer attractive commercial protection.
06NOW REVISIT THE PHRASE “THERE ISN’T ENOUGH EVIDENCE”
It's one of the most common arguments made against experimental peptides.
And frequently it's correct.
For many promoted peptide uses, we do not have the kind of large, high-quality human evidence that should be required before declaring the treatment proven.
But now ask the next question:
Why isn't there enough evidence?
There are several possibilities.
Maybe researchers conducted studies and the compound failed.
Maybe toxicity emerged.
Maybe the mechanism looked promising but didn't translate into meaningful human outcomes.
Maybe early evidence was too weak to justify further investment.
Or:
Maybe nobody had a sufficient economic incentive to spend the money necessary to answer the question.
Those scenarios should not be conflated.
07ABSENCE OF EVIDENCE ISN’T EVIDENCE OF EFFECTIVENESS EITHER
This point must be stated just as strongly.
People sometimes hear:
“Lack of evidence doesn't mean it doesn't work.”
Correct.
Then they make an unjustified leap:
“Therefore it probably works.”
No.
An unanswered question remains unanswered.
A compound does not become effective simply because Big Pharma hasn't funded it.
It could be revolutionary.
It could be mildly helpful.
It could be useless.
It could be harmful.
We need data.
08THIS IS WHY PUBLICLY FUNDED RESEARCH MATTERS
Markets are extraordinarily powerful at generating innovation when commercial incentives align with medical need.
But public research can fill gaps where those incentives don't align.
Imagine a national program specifically designed to investigate promising, commercially neglected therapies.
Selection would be based on transparent criteria:
Strength of preclinical evidence.
Biological plausibility.
Unmet medical need.
Existing human exposure.
Safety signals.
Patient interest.
Potential public-health value.
Lack of adequate private-sector incentives.
Then run real trials.
Not influencer experiments.
Not testimonials.
Not marketing surveys.
Trials.
09IMAGINE WHAT WE COULD FINALLY ANSWER
Does BPC-157 accelerate recovery from a precisely defined tendon injury compared with placebo and standard rehabilitation?
If so, by how much?
Does it change objective imaging?
Return-to-function time?
Reinjury rates?
What adverse events occur?
Does MOTS-C create meaningful metabolic changes in humans?
Do those changes translate into outcomes patients actually care about?
Does Semax produce reproducible benefits for a specific neurological indication?
Does Selank meaningfully affect a defined anxiety disorder?
At what dose?
For how long?
What happens after discontinuation?
Are there immune effects?
What happens with long-term exposure?
Those are answerable questions.
10FDA’S CURRENT CONCERNS SHOULDN’T BE IGNORED
FDA has identified unresolved concerns involving certain compounded peptides, including immunogenicity, aggregation, peptide-related impurities and inadequate human safety information for some substances.
Peptide advocates should confront those concerns directly.
Don't say:
“FDA is just trying to scare people.”
Show the evidence.
If the immunogenicity concern is minimal, demonstrate it.
If manufacturing technology can reliably control impurities, demonstrate it.
If pharmaceutical-grade material is safe under a defined route of administration, demonstrate it.
Good science is the strongest response to regulatory skepticism.
11FOLLOW THE MONEY—IN EVERY DIRECTION
This is where the phrase becomes truly useful.
Yes, follow pharmaceutical money.
Follow lobbying.
Follow patents.
Follow political contributions.
Follow consulting payments.
Follow research funding.
Follow conflicts of interest.
But don't stop when you reach the villain you expected to find.
Follow the money to peptide clinics too.
Compounding pharmacies.
Telehealth businesses.
Supplement companies.
Wellness centers.
Influencers.
Affiliate marketers.
Podcast sponsors.
Doctors.
Hospitals.
Insurance companies.
Universities.
Patient organizations.
Everyone has incentives.
A person telling you:
“Big Pharma doesn't want you to know this secret”
may be selling something five seconds later.
Skepticism that only points in one direction isn't skepticism.
It's confirmation bias.
12THE SAME STANDARD SHOULD APPLY TO EVERYONE
If a pharmaceutical company tells you its drug works:
Show me the trial.
If FDA says a peptide raises safety concerns:
Show me the evidence.
If a peptide clinic says BPC-157 repairs tendons:
Show me the controlled human data.
If an influencer says a product changed their life:
What else changed?
Were they paid?
If Europe prohibits an additive America allows:
Why?
If America disagrees:
Why?
If a study reports dramatic results:
Who funded it?
Was it replicated?
How large was it?
What was the absolute benefit?
What adverse events occurred?
This isn't cynicism.
It's scientific literacy.
13NOW THINK BACK TO WHERE THIS SERIES STARTED
We began in the grocery store.
Food chemicals can remain legally permitted while science continues to evolve.
Regulators can revisit old decisions.
Different countries can examine overlapping evidence and reach different conclusions.
An additive can move from permitted to prohibited.
Then we moved into medicine.
Here the evidentiary burden is understandably higher.
Medicines intentionally alter physiology.
Injected products raise special manufacturing concerns.
Experimental treatments can create risks we don't yet understand.
So rigorous regulation has a legitimate purpose.
But that doesn't end the conversation about autonomy.
It begins it.
14THEN COVID SHOWED US SOMETHING IMPORTANT
During the pandemic, the United States demonstrated that massive clinical research, manufacturing expansion, government financing and regulatory attention can be mobilized rapidly when a problem is considered urgent.
COVID vaccines initially entered U.S. use through EUA.
Pfizer's Comirnaty subsequently received full FDA approval for people 16 and older on August 23, 2021.
The lesson isn't:
“COVID vaccines and experimental peptides are the same.”
They're not.
The lesson is:
Resources and urgency profoundly affect the speed at which evidence can be generated.
So maybe the question isn't simply:
“Why hasn't this peptide been approved?”
Maybe it's:
“Why hasn't this peptide been adequately studied?”
And after that:
“Who has an incentive to find out?”
15IS GOVERNMENT “AGAINST PEPTIDES”?
As a blanket statement, no.
A century of peptide medicine makes that argument difficult to defend.
Successful insulin treatment dates to the early 1920s.
Modern pharmaceutical medicine includes important peptide therapies.
The dispute is over particular compounds, particular claims, evidence quality, manufacturing, safety and legal pathways.
But correcting the oversimplification gives us a much stronger question:
IS OUR SYSTEM GOOD ENOUGH AT INVESTIGATING PROMISING THERAPIES WHEN COMMERCIAL INCENTIVES ARE WEAK?
That's the question worth answering.
16MAYBE WE NEED A NEW CATEGORY OF MEDICAL FREEDOM
Not freedom from evidence.
Freedom with evidence.
Imagine a regulated investigational-access pathway where qualifying adults and physicians could choose certain experimental therapies while contributing anonymized outcome and safety data to national registries.
Manufacturing standards would be strict.
Purity would be independently verified.
Patients would receive explicit disclosures.
Claims couldn't exceed the evidence.
Adverse events would be mandatory to report.
Researchers could analyze outcomes.
Promising signals could trigger randomized trials.
Negative signals could trigger warnings or restrictions.
That would turn experimentation into learning.
17BECAUSE THE CURRENT EXTREMES SERVE NOBODY
One extreme says:
“If FDA hasn't approved it, don't even question the decision.”
The other says:
“If FDA hasn't approved it, that proves they don't want you to have it.”
Both abandon critical thinking.
FDA approval is valuable.
It tells us a product has passed a rigorous regulatory process for specified uses.
But regulators aren't omniscient.
Likewise, regulatory skepticism can be healthy.
But skepticism doesn't transform an unproven treatment into a proven one.
18THE REAL STANDARD IS SIMPLE
Don't tell us whom to trust.
SHOW US THE EVIDENCE.
Show us the human trials.
Show us the animal studies.
Show us the doses.
Show us the adverse events.
Show us the conflicting studies.
Show us the absolute risks.
Show us the absolute benefits.
Show us the manufacturing data.
Show us the purity.
Show us the contaminants.
Show us who funded the research.
Show us who owns the patent.
Show us who lobbied.
Show us who profits.
Show us what FDA concluded.
Show us what European regulators concluded.
Show us what other countries concluded.
Show us where they disagree.
And perhaps most importantly:
SHOW US WHAT YOU STILL DON’T KNOW.
Because those three words—
“We don't know”
—are not evidence that science has failed.
Sometimes they're evidence that science is being honest.
19SO, IS IT ALL ABOUT MONEY?
No.
That's too simplistic.
Safety matters.
Scientific quality matters.
Manufacturing matters.
Law matters.
Public health matters.
Clinical evidence matters.
Money matters too.
And pretending otherwise would be naïve.
Published research has documented billions of dollars in pharmaceutical and health-product lobbying in the United States.
Patents and market exclusivity affect investment.
Commercial opportunity affects which products companies develop.
Those facts justify scrutiny.
They do not prove that every regulatory decision is corrupt.
We don't need a conspiracy theory to examine a system critically.
Structural incentives are powerful enough.
20THE BETTER QUESTION
Instead of asking:
“Is Big Pharma suppressing peptides?”
ask:
ARE THE FINANCIAL INCENTIVES OF OUR MEDICAL-RESEARCH SYSTEM ALWAYS ALIGNED WITH THE QUESTIONS MOST IMPORTANT TO HUMAN HEALTH?
Those two things can overlap.
Often they do.
But not necessarily always.
And when they don't, society needs another mechanism for answering important medical questions.
That's where independent public research matters.
21ONE FINAL CHALLENGE
Question the food manufacturer.
Question the pharmaceutical company.
Question the regulator.
Question the peptide clinic.
Question the compounding pharmacy.
Question the influencer.
Question the politician.
Question the activist.
Question the researcher.
Question the person who tells you everything is safe.
Question the person who tells you everything is toxic.
And yes—
Question this series.
Look up the evidence yourself.
Because independent thinking isn't automatically believing authority.
It isn't automatically rejecting authority either.
It is refusing to outsource your judgment to anyone.
The future of food safety and emerging medicine shouldn't be determined by who can frighten the public most effectively.
It shouldn't be determined by who has the biggest advertising budget.
And it shouldn't be determined by who can shout “misinformation” or “conspiracy” the fastest.
It should be determined by evidence.
And when the evidence doesn't exist?
Don't pretend the answer is known.
DEMAND THE RESEARCH.
22FINAL SERIES DISCLAIMER
This series is educational commentary and is not individualized medical advice.
The phrase “not FDA approved” does not by itself establish that a compound is ineffective or dangerous. It means FDA has not approved that product for the relevant use through its applicable approval process.
Likewise, biological plausibility, animal studies, foreign use, clinician experience and patient testimonials do not by themselves establish that a therapy is safe or effective.
Experimental peptides may have unknown short- and long-term risks. Compounded drugs do not undergo the same FDA premarket approval process for safety, effectiveness and quality as FDA-approved products.
People considering prescription, compounded or investigational therapies should discuss the evidence, alternatives, manufacturing quality, potential benefits and known and unknown risks with an appropriately qualified healthcare professional.
23THE EDITORIAL STANDARD BEHIND THIS SERIES
Four concepts should never be confused:
HAZARD: Can something cause harm under some conditions?
RISK: How likely is meaningful harm under actual human exposure?
EVIDENCE GAP: Do we have enough reliable information to answer the question?
REGULATORY STATUS: What does current law permit or prohibit?
And a fifth belongs beside them:
FINANCIAL INCENTIVE: Who benefits economically from generating—or not generating—particular evidence?
Financial incentives deserve investigation.
They do not substitute for scientific evidence.
The same principle applies to government, pharmaceutical companies, food manufacturers, peptide clinics, compounding pharmacies, researchers, advocacy organizations and influencers.
DON’T REPLACE BLIND TRUST WITH BLIND DISTRUST.
Replace both with informed skepticism.
Research sourcing: a separate question
SAVREN Labs supplies research materials. When evaluating any peptide supplier, ask for independently verifiable identity, purity, and batch-testing documentation. Supplier claims alone do not establish trustworthiness, clinical effectiveness, or safety for human use. Research materials are not substitutes for approved medicines or professional medical care.
Sources & Further Reading
Editorial note
The photographs are AI-generated editorial illustrations, not documented products or evidence of their ingredients. This article is educational analysis, not individual medical advice.